The common stock is listed on the Nasdaq Global Select Market

Davis Polk advised the sales agent in connection with a $125 million SEC-registered at-the-market offering by Alector, Inc. of its common stock. Alector’s common stock is listed on the Nasdaq Global Select Market under the symbol “ALEC.”

Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Sarah Catherine Chouinard and Alex Moss. Partner Frank J. Azzopardi and associate Alison T. Chin provided intellectual property advice. Associate Caroline R. Zhang provided Investment Company Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.